The company boasts a fortress-like balance sheet with significant cash reserves ($8.4 billion in cash at the end of Q3 2025) ...

In a Liv Hospital study, stem cell therapy improved heart function dramatically using MSCs and EVs, despite a blocked graft.

That wide-ranging impact is why Popular Science chose the drops as the 2025 Health category winner. This year’s list also ...

Makatsaria and LivaNova’s leadership outlined the company’s plan for growth during a November Investor Day event. He spoke to ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...

In 2025, the medtech industry saw another year full of all kinds of deals in the mergers and acquisitions (M&A) arena.

Policybazaar for Business has launched AiSHA, an industry-first AI-powered Smart Face Scan and Health Assistant for its ...

From gripping thrillers, witty satires and poignant epics to captivating histories and juicy memoirs, this year’s top reads ...

Objectives This study assessed whether a previously developed Monte Carlo simulation model can be reused for evaluating various strategies to minimise time-to-treatment in southwest Netherlands for ...

Dementia has long been framed as a slow, irreversible loss of neurons, but a new line of research is shifting attention to ...

Interventionalists don’t often order a CXR ahead of time, but when it’s already been done, some find the added info useful.

Artivion stock is outperforming the med-tech sector. Here's what investors need to know about the company and its potential ...